Integra LifeSciences (NASDAQ:IART) PT Lowered to $35.00

Integra LifeSciences (NASDAQ:IART) had its target price decreased by analysts at JMP Securities from $40.00 to $35.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has a “market outperform” rating on the life sciences company’s stock. JMP Securities’ target price would indicate a potential upside of 37.09% from the company’s previous close.

Several other research analysts have also recently issued reports on IART. Morgan Stanley raised their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. BTIG Research lowered shares of Integra LifeSciences from a “neutral” rating to a “sell” rating and set a $22.00 price target on the stock. in a research note on Tuesday. Citigroup cut Integra LifeSciences from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $30.00 to $23.00 in a research report on Tuesday. Bank of America decreased their price objective on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating on the stock in a report on Tuesday, May 7th. Finally, Wells Fargo & Company lowered shares of Integra LifeSciences from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $45.00 to $25.00 in a report on Tuesday, May 7th. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $29.25.

Integra LifeSciences Trading Up 0.4 %

IART stock traded up $0.11 during mid-day trading on Tuesday, reaching $25.53. The company had a trading volume of 980,967 shares, compared to its average volume of 1,121,136. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.68 and a quick ratio of 3.35. The firm has a 50 day moving average of $29.72 and a 200 day moving average of $33.65. Integra LifeSciences has a 12 month low of $22.36 and a 12 month high of $46.09. The company has a market capitalization of $2.01 billion, a PE ratio of 51.06, a price-to-earnings-growth ratio of 1.14 and a beta of 1.11.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a net margin of 2.63% and a return on equity of 14.27%. The firm had revenue of $418.20 million for the quarter, compared to the consensus estimate of $413.07 million. During the same period last year, the firm earned $0.71 earnings per share. The company’s quarterly revenue was up 9.7% on a year-over-year basis. On average, equities analysts predict that Integra LifeSciences will post 3.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Chairman Stuart Essig bought 52,641 shares of the firm’s stock in a transaction on Thursday, May 23rd. The shares were bought at an average cost of $28.49 per share, for a total transaction of $1,499,742.09. Following the acquisition, the chairman now directly owns 487,922 shares of the company’s stock, valued at approximately $13,900,897.78. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Integra LifeSciences

Several large investors have recently modified their holdings of IART. Raymond James & Associates boosted its stake in Integra LifeSciences by 1.4% during the fourth quarter. Raymond James & Associates now owns 207,228 shares of the life sciences company’s stock worth $9,025,000 after buying an additional 2,903 shares during the period. Pacer Advisors Inc. increased its holdings in Integra LifeSciences by 71.9% in the 4th quarter. Pacer Advisors Inc. now owns 10,223 shares of the life sciences company’s stock valued at $445,000 after purchasing an additional 4,276 shares during the last quarter. International Assets Investment Management LLC acquired a new position in Integra LifeSciences during the fourth quarter worth $190,000. Olstein Capital Management L.P. boosted its position in shares of Integra LifeSciences by 4.2% during the fourth quarter. Olstein Capital Management L.P. now owns 74,000 shares of the life sciences company’s stock worth $3,223,000 after buying an additional 3,000 shares during the period. Finally, GHP Investment Advisors Inc. grew its stake in shares of Integra LifeSciences by 9.3% in the fourth quarter. GHP Investment Advisors Inc. now owns 57,724 shares of the life sciences company’s stock valued at $2,514,000 after buying an additional 4,928 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.